{
  "docId": "019de071-68ef-720e-a74a-8410f5ecfd30",
  "docSlug": "0e46fca7c64e4c4db862b8ec0b9f865c",
  "documentTitle": "GreenLight | SPAC Presentation Deck | 56 slides",
  "authorId": "greenlight",
  "authorName": "GreenLight Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 42,
  "pageCount": 56,
  "prevPage": 41,
  "nextPage": 43,
  "slideType": "use_of_funds",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-68ef-720e-a74a-8410f5ecfd30/42",
  "deckHref": "/decks/019de071-68ef-720e-a74a-8410f5ecfd30",
  "deckJsonHref": "/decks/019de071-68ef-720e-a74a-8410f5ecfd30.json",
  "deckAnchorHref": "/decks/019de071-68ef-720e-a74a-8410f5ecfd30#slide-42",
  "components": [
    {
      "bbox": {
        "h": 0.115,
        "w": 0.311,
        "x": 0.649,
        "y": 0.692
      },
      "kind": "list",
      "text": "Build mRNA GMP manufacturing facility; Scale R&D processes, manufacturing capacity, and capabilities; Buy versus make opportunities to accelerate growth and expand product/IP portfolio; Public company G&A costs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ebb9e77-d60f-40dc-aa27-21cb2d32c855",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.311,
        "x": 0.649,
        "y": 0.233
      },
      "kind": "list",
      "text": "Advance COVID-19 and seasonal flu vaccine candidates through clinical trials; Continue R&D efforts on further therapeutics",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ef9119b-0a6e-4c42-bc3e-70fae5fcb473",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.311,
        "x": 0.649,
        "y": 0.465
      },
      "kind": "list",
      "text": "Launch pipeline of pest-protection products and first animal health product into market; Expand into other biological molecules (microbials, peptides, etc.) and applications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eae6a759-4124-41bc-9f3b-7debbc28cff9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.053,
        "w": 0.117,
        "x": 0.112,
        "y": 0.488
      },
      "kind": "metric",
      "text": "$282M",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ca94da6-7a2b-4faa-98f2-f1082bf867df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.189,
        "x": 0.076,
        "y": 0.545
      },
      "kind": "subtitle",
      "text": "(Estimated Cash in Trust and PIPE Proceeds)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d4642b9-92f1-496c-a051-1c44006ece79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.323,
        "x": 0.043,
        "y": 0.078
      },
      "kind": "title",
      "text": "Anticipated use of proceeds",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5454e96-f840-45f4-ab55-49f0b3f901ff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "aa7da2c9-45c4-4e48-b150-a3dd1e64ecc1",
      "evidence": "list/bullet: Build mRNA GMP manufacturing facility; Scale R&D processes, manufacturing capacity, and capabilities; Buy versus make opportunities to accelerate growth and expand product/IP portfolio; Public company G&A costs",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 45,
      "from": 40,
      "beatId": "f30abbc4-7eba-438d-b8c1-e45425edbd18",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Financials",
      "beatSlug": "sequoia-pitch-financials",
      "evidence": "Slides 40-45 present the financial metrics and valuation.",
      "position": 5,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}